clearance
[용어속성] Action
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial
Research Paper
[키워드] Accelerator
adult outpatient
assigned
Azithromycin
cardiac
clearance
Clinical course
clinical outcomes
collected
Comprehensive
conducted
Controlled trial
coronavirus
COVID-19
deaths
double-blind
early treatment
effective therapy
EKG
Endpoint
enrolled
Enrollment
faster
finding
Folic acid
foundation
funding
HCQ
Hospitalization
Hydroxychloroquine
Infection
initiated
laboratory-confirmed SARS-CoV-2 infection
Lower respiratory tract
Mayo Clinic
median
median time
medication
Melinda Gate
morbidity
nasal swab
not differ
occurred
Outpatient
participant
Participants
Prevent
Program
progression
Randomized
randomized clinical trial
Randomized controlled trial
Randomly
receive
recruited
reduce
Remote enrollment
Rice
risk
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 PCR
SARS-CoV-2 transmission
SARS-CoV-2 viral shedding
SARV-CoV-2
Science
secondary endpoint
Seven
severe COVID-19
Smith
stratified
sudden
Support
supported
Symptom
symptom onset
symptom resolution
The United States
Therapeutics
Treatment
University of Washington
viral shedding
vital sign
with COVID-19
[DOI] 10.1016/j.eclinm.2021.100773 PMC 바로가기 [Article Type] Research Paper
[DOI] 10.1016/j.eclinm.2021.100773 PMC 바로가기 [Article Type] Research Paper
Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients
Clinical Trial
[키워드] 95% CI
Admission
age
analyzed
Asymptomatic
asymptomatic patient
caused
Characteristics
clearance
clinical
clinical feature
clinical symptom
collected
Comorbidities
Comorbidity
Computed tomography
coronavirus disease
COVID-19
COVID-19 pandemic
Delayed
discharged patient
evaluate
evaluated
Factor
global public health
identify
illness onset
infected with SARS-CoV-2
interquartile range
involved
IQR
laboratory-confirmed
male
median time
Mortality
Multiple linear regression
objective
outbreak
outcome
Patient
patients with COVID-19
Pneumonia
predict
predictor
reduce
Registered
Result
SARS-CoV-2
SARS-CoV-2 infections
SARS-CoV-2 RNA
SARS-CoV-2 RNA detection
significant difference
Spread
symptomatic patient
the median
Trial
Trial Registration Number
viral clearance
viral persistence
virus
[DOI] 10.1155/2021/5909612 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1155/2021/5909612 PMC 바로가기 [Article Type] Clinical Trial
Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients
Clinical Trial
[키워드] 95% CI
Admission
age
analyzed
Asymptomatic
asymptomatic patient
caused
Characteristics
clearance
clinical
clinical feature
clinical symptom
collected
Comorbidities
Comorbidity
Computed tomography
coronavirus disease
COVID-19
COVID-19 pandemic
Delayed
discharged patient
evaluate
evaluated
Factor
global public health
identify
illness onset
infected with SARS-CoV-2
interquartile range
involved
IQR
laboratory-confirmed
male
median time
Mortality
Multiple linear regression
objective
outbreak
outcome
Patient
patients with COVID-19
Pneumonia
predict
predictor
reduce
Registered
Result
SARS-CoV-2
SARS-CoV-2 infections
SARS-CoV-2 RNA
SARS-CoV-2 RNA detection
significant difference
Spread
symptomatic patient
the median
Trial
Trial Registration Number
viral clearance
viral persistence
virus
[DOI] 10.1155/2021/5909612 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1155/2021/5909612 PMC 바로가기 [Article Type] Clinical Trial
Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients
경증 COVID-19에서 바이러스 제거에 영향을 미치는 요인 및 무증상 환자의 임상 특성
Clinical Trial
[키워드] 95% CI
Admission
age
analyzed
Asymptomatic
asymptomatic patient
Beta
caused
Characteristics
clearance
clinical
clinical feature
Clinical features
clinical symptom
collected
Comorbidities
Comorbidity
Computed tomography
coronavirus
coronavirus disease
COVID-19
COVID-19 pandemic
Delayed
discharged patient
discharged patients
evaluate
evaluated
Factor
global public health
global public health emergency
identify
illness onset
infected with SARS-CoV-2
interquartile range
involved
IQR
laboratory-confirmed
male
median age
median time
Mortality
Multiple linear regression
no significant differences
objective
outbreak
outcome
Patient
patients with COVID-19
Pneumonia
predict
predictor
reduce
Registered
registration number
Result
SARS-CoV-2
SARS-CoV-2 infections
SARS-CoV-2 RNA
SARS-CoV-2 RNA detection
significant difference
Spread
symptomatic patient
the median
Trial
Trial Registration Number
Viral
viral clearance
viral persistence
virus
[DOI] 10.1155/2021/5909612 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1155/2021/5909612 PMC 바로가기 [Article Type] Clinical Trial
Protocol for a patient-reported experience measures (PREMs) survey of patients discharged during the COVID-19 pandemic and their family caregivers
COVID-19 팬데믹 기간 동안 퇴원한 환자 및 가족 간병인에 대한 PREM(환자 보고 경험 측정) 조사 프로토콜
Article
[키워드] Anderson
Care
clearance
collected
communication
Complete
COVID-19
COVID-19 hospitalisation
COVID-19 pandemic
discharged
discharged home
discharged patient
discharged patients
Effect
ethical clearance
Ethics
ethics committee
examined
Families
Family caregivers
feeling
Health
health &
Health services
healthcare
hospital
hospitalised
Human
Human Research Ethics Committee
include
inferential statistics
Intervention
measure
Nurse
Nurses
open
Organisation of health services
Pandemics
participant
Patient
Perceived stress
Perceived Stress Scale
Perception
physician
public health
quality in healthcare
question
questionnaire
recommendation
Research Ethics
Risk perception
Safety
SARS-CoV-2
SARS-COV-2 infection
scale
second wave
social determinant
social determinants
Stress Scale
Support
surgery
the patient
thematic analysis
trajectory
Trust
undergo
[DOI] 10.1136/bmjopen-2020-047033 PMC 바로가기 [Article Type] Article
[DOI] 10.1136/bmjopen-2020-047033 PMC 바로가기 [Article Type] Article
Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19
Immunology
[키워드] accelerated
alteration
Antiviral effect
application
autophagy
Azithromycin
benefit
clearance
Clinical use
contribute
Course
COVID-19
COVID-19 immune response
COVID-19 pandemic
Cytokine storm
death
defined
early stage
Effect
effective
Efficacy
Evidence
Factor
function
identify
immune mechanism
immune response
immunomodulation
immunomodulatory
immunomodulatory effect
immunomodulatory therapy
immunosuppressive
Infection
Inflammation
inflammatory cell infiltration
investigated
late stage
Lung pathology
macrophages
mechanism
Multiple
neutrophil
patients
patients with COVID-19
Potential
pro-inflammatory cytokine
progression
pursuit
Regulatory
severe disease
shown
Stage
Support
the disease
therapeutic
therapy
viral burden
virus
while
[DOI] 10.3389/fimmu.2021.574425 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2021.574425 PMC 바로가기 [Article Type] Immunology
Time to SARS‐CoV‐2 clearance among patients with cancer and COVID‐19
Original Research
[키워드] acute respiratory syndrome
Cancer
Cancer center
cancer patient
Cancer patients
Cancer therapy
Care
CDC
CDC criteria
center
Chemotherapy
clearance
clinical
clinical criteria
Cohort
Control
coronavirus
coronavirus disease
COVID‐19
COVID‐19
criteria
expected
extension
first positive
hospital
Infection
infection control
less
median
median time
nasopharyngeal
Patient
Patients with cancer
polymerase chain
positive
precautions
prevention
Result
retrospective cohort study
RT‐PCR
SARS‐CoV‐2
Society
Symptoms
the median
time
transcriptase
[DOI] 10.1002/cam4.3708 PMC 바로가기 [Article Type] Original Research
[DOI] 10.1002/cam4.3708 PMC 바로가기 [Article Type] Original Research
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial
COVID19에 감염된 종양-혈액학적 환자에서 호흡 부전 진행을 예방하기 위한 바리시티닙의 효능을 평가하기 위한 I/II상 임상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
AAK1
absence
activator
Acute respiratory failure
Administered
administration
Adverse
adverse events
affected
alkaline phosphatase
All participants
allergy
Alpha
alpha error
angina pectoris
Antibiotics
appearance
ARDS
Arm
assigned
AST/ALT
Baricitinib
baseline
beta error
Bilirubin
Blinding
Blood
Breastfeeding
can be used
candidate
Candidates
capture
Cardiac arrhythmia
carried
change
clearance
clinical
clinical condition
clinical suspicion
clinical trials
Coagulation
Cohort
Common Terminology Criteria
Comorbidity
Complete
completion
Compliance
congestive heart failure
control arm
Controlled trial
corticoid
Corticosteroids
COVID19
creatinine
creatinine clearance
CRP
D-dimer
Day
Deep venous thrombosis
description
Deterioration
Dexamethasone
dimer
discharge
discretion
disease
dissemination
diverticulitis
dose
dropout rate
Duration of therapy
ECMO
Efficacy
electronic case report form
element
eligibility criteria
Enrollment
evaluate
exclusion criteria
expected
experimental arm
extracorporeal membrane oxygenation
febrile neutropenia
ferritin
followed by
form
fraction
Gas exchange
greater
HBV
HCV
hemodynamic instability
High-flow nasal cannula
HIV
HIV infection
ICU
immobilization
immunological
impossibility
incidence
include
indication
Infection
infection with SARS-CoV-2
Inflammatory response
interfere
interferon
Interim
interim analysis
interleukin
interleukin 6
interstitial pneumonia
Intervention
intestinal perforation
Invasive mechanical ventilation
investigational agent
investigator
jak inhibitors
Jak-STAT
Laboratory
laboratory parameter
Laboratory parameters
LDH
less
limit
limits
management
mechanical ventilation
medical history
Medicine
meet
Methylprednisolone
Mild ARDS
Mortality
multi organ failure
nasal
nasal cannula
need for oxygen
neutropenia
neutrophil
Neutrophils
Non-invasive
number
objective
on mechanical ventilation
oncological patients
onset of symptom
open
open label
oral medication
organ dysfunction
Organ failure
outcome
oxygen
oxygen support
PaFi
participant
Participants
Participation
pathogen
Pathogens
pathway
Patient
patients
performance status
performed
phase
Phase 1
Phase 2
Phase I
phosphatase
platform
Pneumonia
poor prognosis
positive
Prednisone
pregnancy test
pregnant
prejudice
Prevent
progression
Prophylaxis
Protein
protein kinase
protocol
Psychiatric
psychiatric illness
Pulmonary embolism
radiological
randomisation
randomised
randomised controlled trial
randomization
Randomized
Randomized controlled trial
receive
receptor
recruitment
REDCap
REDcap platform
reduce
reduced
Remdesivir
removal
report
reported
required
respiratory
Respiratory failure
Respiratory function
respiratory insufficiency
respiratory tract
Sample size
SARS-CoV-2
SARS-CoV2
SARS-CoV2 infection
Secondary objectives
Sepsis
severe adverse event
severe adverse events
severe pneumonia
severe respiratory failure
Spain
Spanish
Standard of care
STAT
status
study enrollment
Study protocol
supplemental oxygen requirement
supplemental oxygen requirements
supplementary material
Support
surgical
surgical intervention
Symptom
symptomatic
Tablet
Therapies
therapy
thromboembolic disease
thrombosis
Tocilizumab
total bilirubin
Toxicity
Transcription
transducer
Treatment
treatment period
Trial
unstable angina
use of corticosteroid
Venous thrombosis
Version
viral endocytosis
website
Withdrawal
worsening
[DOI] 10.1186/s13063-021-05072-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05072-4 PMC 바로가기 [Article Type] Letter
Targeting Lipid Rafts as a Strategy Against Coronavirus
Cell and Developmental Biology
[키워드] ACE-2
ACE-2 receptor
acute respiratory syndrome
Affect
affecting
Against
Alpha
angiotensin-converting enzyme-2
Antiviral compounds
approach
autophagic
bind
binding
Bioavailability
characterized
cholesterol
clearance
complexes
component
coronavirus
Coronavirus-2
Coronaviruses
cyclodextrins
domain
downstream
drug
functional
host cell
host cell membrane
host cell surface
impairing
Inclusion
involved
Lipid
Lipid rafts
main receptor
membrane
N-terminal
Necrosis
pharmacological
platform
proinflammatory molecule
raft
reducing
Region
Remdesivir
SARS-CoV-2
selective
sialic acid
sphingolipids
Spike protein
statins
Strategy
targeting
the SARS-CoV-2
the spike protein
these compound
TNF-α
viral envelope
viral replication
virus infectivity
viruses
[DOI] 10.3389/fcell.2020.618296 PMC 바로가기 [Article Type] Cell and Developmental Biology
[DOI] 10.3389/fcell.2020.618296 PMC 바로가기 [Article Type] Cell and Developmental Biology